jazz pharmaceuticals
Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth
July 16, 2025Research and Development CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience
Jazz Pharmaceuticals has named Renée Galá as its next chief executive officer (CEO), effective 11 August 2025. Galá, currently president …
Jazz Pharmaceuticals enters agreement to acquire rights to KRAS inhibitor programme from Redx Pharma
February 7, 2024Business Services Pharmacy, RedX Pharma, acquisition, jazz pharmaceuticals
Jazz Pharmaceuticals and Redx Pharma have announced that the companies have signed a definitive agreement under which Jazz will acquire …
Autifony announces global license and collaboration agreement with Jazz Pharmaceuticals
November 14, 2023Business Services Autifony, Neurology, collaboration, jazz pharmaceuticals, neurological disorders
Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz Pharmaceuticals for up to $770.5m, …
Jazz acquires GW Pharmaceuticals in $7.2 billion deal
February 4, 2021cannabinoid, jazz pharmaceuticals
Jazz Pharmaceuticals has acquired GW Pharmaceuticals for over $7 billion, with the transition expected to close in the second quarter …
Jazz Pharma’s Sunosi becomes first EU-approved drug of its kind in narcolepsy and sleep apnoea
January 21, 2020Manufacturing and Production, Sales and Marketing jazz pharmaceuticals, narcolepsy, pharma
Jazz Pharmaceuticals has secured approval from the European Commission for Sunosi (solriamfetol), it has emerged, as a therapy to improve …
FDA authorises Jazz Pharma’s sleep disorder therapy Sunosi
March 22, 2019Medical Communications, Sales and Marketing FDA, jazz pharmaceuticals, pharma, sleep apnoea
Jazz Pharmaceuticals has announced that its dopamine and norepinephrine reuptake inhibitor (DNRI) Sunosi (solriamfetol) has been approved by the FDA …
Jazz Pharma’s Vyxeos secures NICE recommendation in acute myeloid leukaemia
November 8, 2018Sales and Marketing Cancer, NHS, NICE, UK, Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, pharma
Jazz Pharmaceuticals has revealed that NICE has chosen to recommend that its 44mg/100mg powder formulation of Vyxeos for concentrate for …
Jazz Pharma’s acute myeloid leukaemia drug scores EU approval
August 29, 2018Research and Development, Sales and Marketing Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, leukaemia, pharma
Jazz Pharmaceuticals has revealed that its advanced liposomal formulation Vyxeos has received approval from the European Commission for the treatment …
Jazz Pharmaceuticals to expand Irish workforce across Dublin, Athlone sites
August 6, 2018Manufacturing and Production, Sales and Marketing Dublin, Ireland, jazz pharmaceuticals, pharma
Jazz Pharmaceuticals has announced its intention to expand its staff numbers at two of its bases in its home country …
Jazz Pharmaceuticals UK supplier hit with FDA warning
January 26, 2017Manufacturing and Production Erwinaze, Porton Biopharma, jazz pharmaceuticals
UK-based Porton Biopharma, supplier of Irish company Jazz Pharmaceuticals’ leukaemia treatment Erwinaze, has been slapped with an FDA warning letter …
Jazz Pharmaceuticals receives FDA approval for rare veno-occlusive disease treatment
March 31, 2016Research and Development, Sales and Marketing FDA, jazz pharmaceuticals
Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that the US Food and Drug Administration (FDA) has granted marketing approval for Defitelio …
